Understanding Treatment-Resistant Depression and SPRAVATO® in Evanston, Wyoming

For many individuals diagnosed with Major Depressive Disorder (MDD), counseling (psychotherapy) and medications can significantly alleviate symptoms. However, when these treatments fail to provide sufficient relief despite adherence to appropriate care, the condition may be classified as treatment-resistant depression (TRD). According to the FDA, TRD is defined as an inadequate response to at least two different antidepressant treatments, each taken at an adequate dose and duration (typically 6-8 weeks) during a depressive episode.

What Is SPRAVATO®?

SPRAVATO® (esketamine) is an innovative prescription nasal spray approved by the FDA for adults with treatment-resistant depression. Unlike traditional antidepressants, which primarily target neurotransmitters like serotonin, norepinephrine, and dopamine, SPRAVATO® acts on the N-methyl-D-aspartate (NMDA) receptor. Although its exact mechanism of action remains under investigation, clinical studies have demonstrated promising outcomes for patients with TRD.

Benefits of SPRAVATO®

• Short-Term Benefits: In a clinical trial, adults using SPRAVATO® alongside an oral antidepressant experienced a significantly greater reduction in depressive symptoms within four weeks compared to those using a placebo and an oral antidepressant.
• Long-Term Benefits: After 16 weeks of therapy, patients who continued with SPRAVATO® treatment were less likely to relapse into depression compared to those who discontinued the medication.
• Your healthcare provider will assess whether SPRAVATO® is appropriate for your unique needs.

Potential Side Effects of SPRAVATO®

As with any medication, SPRAVATO® may cause side effects. Some of the more serious potential effects include:

• Sedation or drowsiness
• A sense of disconnection or dissociation
• Risk of misuse or dependency
• Increased suicidal thoughts or behaviors
• Elevated blood pressure
• Cognitive difficulties
• Bladder issues

Most side effects occur shortly after administration and typically subside the same day. For a full list of risks and considerations, consult the SPRAVATO® Medication Guide or speak with your healthcare provider.

Preparing for Treatment with SPRAVATO®

SPRAVATO® is a Schedule III controlled substance and must be administered under direct supervision at a certified treatment center. During your session:

• Plan Ahead: Arrange transportation, as driving or operating heavy machinery is not permitted until the day after treatment, following a full night’s sleep.
• Bring Entertainment: Consider bringing a book, music, or other calming activities to occupy your time during observation.
• Dietary Guidelines: Avoid eating for at least two hours and drinking liquids 30 minutes before your session, as nausea or vomiting is a possible side effect.
• A healthcare provider will monitor you for at least two hours post-treatment to ensure your safety and comfort.

Is SPRAVATO® Right for You?

Not everyone is a candidate for SPRAVATO®. Your healthcare provider will carefully evaluate your medical history and symptoms to determine if this treatment aligns with your needs. If you'd like to learn more, ask your provider or explore the SPRAVATO® informational video. By working with a certified treatment center and following the guidance of your healthcare team, you can explore SPRAVATO® as a potential option for managing treatment-resistant depression and reclaiming your quality of life.